Supplementation During Endurance PerformanceNCT07611877
Ecklonia Cava Supplementation and Cycling Performance
A study testing Supplement in people with Supplementation During Endurance Performance, run by University of Exeter at 1 site in United Kingdom.
Trial summary
The goal of this clinical trial (randomised, double-blind, placebo-controlled crossover study) is to investigate whether supplementation with Ecklonia cava, a natural extract derived from brown seaweed, affects exercise performance and physiological responses in trained cyclists. Read more about this study
- Who is it for?
- Ages 18 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Supplementation During Endurance Performance
- What is being tested?
- Supplement
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 12 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 1 Mar 2020to 2 Dec 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- experienced in cycling (defined as completing at least four hours of cycle training per week with a minimum of two years of experience)
Who cannot join
- Smoker
- cardiovascular disease
- anti-hypertensive medication
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Department of Applied and Human Sciences
Kingston upon Thames, KT1 2EE
About this study
Official title: Acute Ecklonia Cava Supplementation Fails to Enhance Performance in Trained Cyclists
The goal of this clinical trial (randomised, double-blind, placebo-controlled crossover study) is to investigate whether supplementation with Ecklonia cava, a natural extract derived from brown seaweed, affects exercise performance and physiological responses in trained cyclists.
The main questions it aims to answer are:
Read more
Does Ecklonia cava supplementation improve cycling performance, including power output during steady-state exercise and short maximal sprints? Does Ecklonia cava supplementation influence physiological responses to exercise, such as blood glucose, blood lactate, heart rate, and oxygen consumption?
Researchers will compare Ecklonia cava supplementation to a placebo (a look-alike substance with no active ingredients) to determine whether the supplement has any effect on performance or physiological responses.
In this crossover design, all participants will receive both the Ecklonia cava supplement and the placebo on separate occasions, with a washout period between conditions.
Participants will:
Ingest either Ecklonia cava or a placebo 30 minutes before exercise testing Complete a 60-minute cycling protocol at a moderate intensity Perform repeated short-duration maximal sprint efforts following the steady-state exercise Attend laboratory testing sessions under both supplement and placebo conditions Undergo measurements of physiological responses, including blood glucose, blood lactate, heart rate, oxygen consumption, and respiratory exchange ratio Have exercise performance assessed through measures of power output during cycling
- Being tested
- Placebo, Supplement
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PlaceboDietary supplement
Placebo Supplementation
SupplementDietary supplement
Ecklonia Cava Supplementation
| Study group | Role | What they receive |
|---|---|---|
| Placebo Supplementation | Placebo comparator | Not described Receives: Dietary Supplement: Placebo |
| Ecklonia Cava Supplementation | Experimental | Not described Receives: Dietary Supplement: Supplement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Peak Power Output During Sprint Performance (Watts)
Peak power output achieved during 20-second maximal sprint efforts performed following a fixed-intensity (55% Wmax) 60-minute cycling protocol
Measured: Immediately after the 60-minute submaximal cycling protocol, 30 minutes after supplementation
Mean Power Output During Sprint Performance (Watts)
Mean power output recorded during repeated 20-second maximal sprint efforts following steady-state cycling
Measured: Immediately after the 60-minute submaximal cycling protocol, 30 minutes after supplementation
Blood Lactate Concentration During Sprint Cycling (mmol/L)
Blood lactate concentration measured following each repeated sprint efforts (3)
Measured: Repeated sprint cycling (3) completed immediately after the 60-minute submaximal cycling protocol, a blood sample taken 2 minutes after each sprint cycling bout. Following each 30-minute supplementation protocol.
Blood Glucose Concentration During Sprint Cycling (mmol/L)
Blood glucose concentration measured following repeated sprint efforts
Measured: Repeated sprint cycling (3) completed immediately after the 60-minute submaximal cycling protocol, a blood sample taken 2 minutes after each sprint cycling bout. Following each 30-minute supplementation protocol.
Secondary outcomes (5)
Heart Rate During Submaximal Cycling (beats per minute)
Average heart rate measured during a 60-minute steady-state cycling protocol performed at 55% maximal power output
Measured: During the 60-minute submaximal cycling protocol, 30 minutes after supplementation (each condition)
Blood Lactate Concentration During Submaximal Cycling (mmol/L)
Blood lactate concentration measured during steady-state cycling at 55% maximal power output
Measured: Every 20-minutes during the 60-minute submaximal cycling protocol, 30 minutes after supplementation
Blood Glucose Concentration During Submaximal Cycling (mmol/L)
Blood glucose concentration measured during steady-state cycling at 55% maximal power output
Measured: Every 20-minutes during the 60-minute submaximal cycling protocol, 30 minutes after supplementation
Oxygen Consumption (VO₂) During Submaximal Cycling (ml/kg/min)
Oxygen consumption measured using indirect calorimetry during steady-state cycling
Measured: During the 60-minute submaximal cycling protocol, 30 minutes after supplementation
Respiratory Exchange Ratio (RER) During Submaximal Cycling
Respiratory exchange ratio measured during steady-state cycling using expired gas analysis
Measured: During the 60-minute submaximal cycling protocol, 30 minutes after supplementation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 May 2026
- Study start1 Mar 2020
- Primary completion21 Sep 2020
- Study completion2 Dec 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Supplementation During Endurance PerformanceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 12 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Exeter
- Sponsor type
- University, hospital or other
- Collaborators
- Kingston University
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07611877
- Sponsor's protocol ID
- 1501
- Status last verified
- May 2026
- First submitted
- 5 May 2026
- Last updated
- 28 May 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Available on request.
Study at a glance
From the registry record, last updated by the sponsor on 28 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Acute Ecklonia Cava Supplementation Fails to Enhance Performance in Trained Cyclists
- ClinicalTrials.gov ID
- NCT07611877
- Acronym / sponsor ID
- 1501
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 12 participants (actual)
- Lead sponsor
- University of ExeterUniversity, hospital or other
- Collaborators
- Kingston University
- Study start
- 1 Mar 2020 (actual)
- Primary completion
- 21 Sep 2020 (actual)
- Study completion
- 2 Dec 2020 (actual)
- First posted
- 28 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial (randomised, double-blind, placebo-controlled crossover study) is to investigate whether supplementation with Ecklonia cava, a natural extract derived from brown seaweed, affects exercise performance and physiological responses in trained cyclists.
The main questions it aims to answer are:
Does Ecklonia cava supplementation improve cycling performance, including power output during steady-state exercise and short maximal sprints? Does Ecklonia cava supplementation influence physiological responses to exercise, such as blood glucose, blood lactate, heart rate, and oxygen consumption?
Researchers will compare Ecklonia cava supplementation to a placebo (a look-alike substance with no active ingredients) to determine whether the supplement has any effect on performance or physiological responses.
In this crossover design, all participants will receive both the Ecklonia cava supplement and the placebo on separate occasions, with a washout period between conditions.
Participants will:
Ingest either Ecklonia cava or a placebo 30 minutes before exercise testing Complete a 60-minute cycling protocol at a moderate intensity Perform repeated short-duration maximal sprint efforts following the steady-state exercise Attend laboratory testing sessions under both supplement and placebo conditions Undergo measurements of physiological responses, including blood glucose, blood lactate, heart rate, oxygen consumption, and respiratory exchange ratio Have exercise performance assessed through measures of power output during cycling
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Placebo Supplementation | Placebo comparator | Dietary Supplement: Placebo |
| Ecklonia Cava Supplementation | Experimental | Dietary Supplement: Supplement |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- experienced in cycling (defined as completing at least four hours of cycle training per week with a minimum of two years of experience)
Key exclusion criteria (3 listed)
- Smoker
- cardiovascular disease
- anti-hypertensive medication
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PlaceboPlacebo Supplementation | Dietary supplement | Placebo Supplementation |
| SupplementEcklonia Cava Supplementation | Dietary supplement | Ecklonia Cava Supplementation |
Primary outcome
Peak Power Output During Sprint Performance (Watts)
Time frame: Immediately after the 60-minute submaximal cycling protocol, 30 minutes after supplementation
Peak power output achieved during 20-second maximal sprint efforts performed following a fixed-intensity (55% Wmax) 60-minute cycling protocol
Mean Power Output During Sprint Performance (Watts)
Time frame: Immediately after the 60-minute submaximal cycling protocol, 30 minutes after supplementation
Mean power output recorded during repeated 20-second maximal sprint efforts following steady-state cycling
Blood Lactate Concentration During Sprint Cycling (mmol/L)
Time frame: Repeated sprint cycling (3) completed immediately after the 60-minute submaximal cycling protocol, a blood sample taken 2 minutes after each sprint cycling bout. Following each 30-minute supplementation protocol.
Blood lactate concentration measured following each repeated sprint efforts (3)
Blood Glucose Concentration During Sprint Cycling (mmol/L)
Time frame: Repeated sprint cycling (3) completed immediately after the 60-minute submaximal cycling protocol, a blood sample taken 2 minutes after each sprint cycling bout. Following each 30-minute supplementation protocol.
Blood glucose concentration measured following repeated sprint efforts
5 secondary outcomes
Heart Rate During Submaximal Cycling (beats per minute)
Time frame: During the 60-minute submaximal cycling protocol, 30 minutes after supplementation (each condition)
Blood Lactate Concentration During Submaximal Cycling (mmol/L)
Time frame: Every 20-minutes during the 60-minute submaximal cycling protocol, 30 minutes after supplementation
Blood Glucose Concentration During Submaximal Cycling (mmol/L)
Time frame: Every 20-minutes during the 60-minute submaximal cycling protocol, 30 minutes after supplementation
Oxygen Consumption (VO₂) During Submaximal Cycling (ml/kg/min)
Time frame: During the 60-minute submaximal cycling protocol, 30 minutes after supplementation
Respiratory Exchange Ratio (RER) During Submaximal Cycling
Time frame: During the 60-minute submaximal cycling protocol, 30 minutes after supplementation
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 May 2026.
- Individual participant dataSharing planned: Yes. Available on request.
Related trials for Supplementation During Endurance Performance
Enrolling by invitation
Effects of Vitamin B12 and Natural Orange Extract, and Their Combination on Physical and Mental Performance
Vitamin b12, Supplementation During Endurance Performance
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Supplement in people with Supplementation During Endurance Performance, run by University of Exeter at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Peak Power Output During Sprint Performance (Watts) (time frame: Immediately after the 60-minute submaximal cycling protocol, 30 minutes after supplementation). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 May 2026; AzTrials last refreshed its copy on 30 Oct 2026.